Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study

Rupsa C. Boelig; Mariam Wanees; Tingting Zhan; Vincenzo Berghella; Amanda Roman

doi:10.1055/s-0040-1718580

American Journal of Perinatology, Table of Contents

Am J Perinatol 2021; 38(06): 544-552
DOI: 10.1055/s-0040-1718580

SMFM Fellowship Series Article

Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study

Rupsa C. Boelig

¹Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Mariam Wanees

¹Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Tingting Zhan

²Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Vincenzo Berghella

¹Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

,

Amanda Roman

¹Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

› Author Affiliations

Abstract

Objective This study aimed to evaluate the utilization of aspirin for preeclampsia prevention before and after implementation of a screening tool during nuchal translucency (NT) ultrasound.

Study Design One-year prospective cohort study of patients at high risk for preeclampsia after the implementation of a screening tool (postscreen) administered to all patients at check in for NT (11–13 weeks) ultrasound. Prospective cohort was compared with one-year retrospective cohort (prescreen) the year prior (2017). All patients who presented for NT ultrasound in both cohorts were evaluated for the presence of one or more risk factor for preeclampsia with screening tool collected prospectively and chart review retrospectively. Provider recommendation for aspirin determined by documentation in prenatal record. Primary outcome was rate of provider recommendation for aspirin pre versus post screening tool, compared by Chi-square test and adjusted for potential confounders with multiple regression analysis.

Results Pre- (n = 156) and postscreen (n = 136) cohorts were similar except for race and multifetal gestation. Prescreen, rate of provider recommendation for aspirin was 74%. Of those with prior preeclampsia, 96% were recommended aspirin, compared with 64% of patients with other risk factors (p < 0.001). Postscreen, provider recommendation of aspirin improved to 95% (p < 0.001). Rate of preeclampsia/gestational hypertension were similar between cohorts; however, there was a reduced adjusted risk in overall preterm birth <37 weeks (adjusted odds ratio [aOR] = 0.50 [0.25–0.99]) and preterm birth <34 weeks (aOR = 0.33 [0.13–0.88]) postscreening tool implementation.

Conclusion Prior to implementation of a simple screening questionnaire, approximately 25% of high risk patients did not receive the recommendation of aspirin for preeclampsia prevention. High-risk patients who lack a history of preeclampsia were less likely to be advised of aspirin prophylaxis. Use of a simple universal screening tool at time of NT ultrasound significantly improved utilization of aspirin for preeclampsia prevention and may improve patient outcomes.

Key Points

Despite recommendations, aspirin use for preeclampsia prevention is suboptimal.
High-risk patients who lack a history preeclampsia were less likely to be advised of aspirin use.
A simple universal screening tool can significantly improve aspirin utilization.

Keywords

aspirin - preeclampsia - implementation research

Full Text

References

References
1 Wong AE, Grobman WA. Medically indicated--iatrogenic prematurity. Clin Perinatol 2011; 38 (03) 423-439
2 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
3 ACOG, Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia: Updated Recommendations. Available at: http://www.losolivos-obgyn.com/info/md/acog/Low-dose%20aspirin,%20ACOG%20Practice%20Advisory%202016.pdf. Accessed December 28, 2017
4 US Preventive Services Task Force, Final recommendation statement: low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: preventive medication. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication. Accessed December 28, 2017
5 ACOG, Practice advisory on low dose aspirin and prevention of preeclampsia: updated recommendations. Available at: http://www.losolivos-obgyn.com/info/md/acog/Low-dose%20aspirin,%20ACOG%20Practice%20Advisory%202016.pdf. Accessed September 22, 2020
6 Neta G, Brownson RC, Chambers DA. Opportunities for epidemiologists in implementation science: a primer. Am J Epidemiol 2018; 187 (05) 899-910
7 Hull L, Athanasiou T, Russ S. Implementation science. Ann Surg 2017; 265 (06) 1104-1112
8 Ayala NK, Rouse DJ. A nudge toward universal aspirin for preeclampsia prevention. Obstet Gynecol 2019; 133 (04) 725-728
9 Tolcher MC, Chu DM, Hollier LM. et al. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. Am J Obstet Gynecol 2017; 217 (03) 365.e1-365.e8
10 Banala C, Moreno S, Cruz Y. et al. Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension. Am J Obstet Gynecol 2020; 223 (03) 419.e1-419.e16
11 Persson M, Winkvist A, Mogren I. Surprisingly low compliance to local guidelines for risk factor based screening for gestational diabetes mellitus - a population-based study. BMC Pregnancy Childbirth 2009; 9 (01) 53
12 Boelig RC, Jiang E, Scheidemantle B, Villani M, Berghella V. Utilization of progesterone and cervical length screening for prevention of recurrent preterm birth. J Matern Fetal Neonatal Med 2018; 32 (24) 4146-4153
13 Orsulak MK, Block-Abraham D, Gee RE. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population. Clin Ther 2015; 37 (04) 727-732
14 Iams JD, Applegate MS, Marcotte MP. et al. A statewide progestogen promotion program in Ohio. Obstet Gynecol 2017; 129 (02) 337-346
15 Temming LA, Durst JK, Tuuli MG. et al. Universal cervical length screening: implementation and outcomes. Am J Obstet Gynecol 2016; 214 (04) 523.e1-523.e8
16 Orzechowski KM, Nicholas SS, Baxter JK, Weiner S, Berghella V. Implementation of a universal cervical length screening program for the prevention of preterm birth. Am J Perinatol 2014; 31 (12) 1057-1062
17 Son M, Grobman WA, Ayala NK, Miller ES. A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate. Am J Obstet Gynecol 2016; 214 (03) 365.e1-365.e5
18 Orzechowski KM, Boelig RC, Baxter JK, Berghella V. A universal transvaginal cervical length screening program for preterm birth prevention. Obstet Gynecol 2014; 124 (03) 520-525
19 Wright D, Poon LC, Rolnik DL. et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol 2017; 217 (06) 685.e1-685.e5
20 Roberge S, Bujold E, Nicolaides KH. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol 2018; 218 (05) 483-489

Supplementary Material

Supplementary Material